
Epidemiology and survival of adult-type diffuse glioma in Belgium during the molecular era
- Author
- Harry Pinson (UGent) , Geert Silversmit, Dimitri Vanhauwaert (UGent) , Katrijn Vanschoenbeek, Jean-Pierre Kalala Okito (UGent) , Steven De Vleeschouwer, Tom Boterberg (UGent) and Cindy De Gendt
- Organization
- Abstract
- Background Survival data of diffuse adult-type glioma is mostly based on prospective clinical trials or small retrospective cohort studies. Real-world data with large patient cohorts is currently lacking.Methods Using the nationwide, population-based Belgian Cancer Registry, all known histological reports of patients diagnosed with an adult-type diffuse glioma in Belgium between 2017 and 2019 were reviewed. The ICD-O-3 morphology codes were matched with the histological diagnosis. The gathered data were transformed into the 2021 World Health Organization classification of CNS tumors using the IDH- and 1p/19q-mutation status.Results Between 2017 and 2019, 2233 diffuse adult-type gliomas were diagnosed in Belgium. Full molecular status was available in 67.1% of identified cases. The age-standardized incidence rate of diffuse adult-type glioma in Belgium was estimated at 8.55 per 100 000 person-years and 6.72 per 100 000 person-years for grade 4 lesions. Median overall survival time in IDH-wild-type glioblastoma was 9.3 months, significantly shorter compared to grade 4 IDH-mutant astrocytoma (median survival time: 25.9 months). The 3-year survival probability was 86.0% and 75.7% for grades 2 and 3 IDH-mutated astrocytoma. IDH-wild-type astrocytoma has a worse prognosis with a 3-year survival probability of 31.6% for grade 2 and 5.7% for grade 3 lesions.Conclusions This registry-based study presents a large cohort of adult-type diffuse glioma with known molecular status and uses real-world survival data. It adds to the current literature which is mainly based on historical landmark trials and smaller retrospective cohort studies.
- Keywords
- diffuse adult-type glioma, epidemiology, survival, RANDOMIZED PHASE-III, CENTRAL-NERVOUS-SYSTEM, ADJUVANT TEMOZOLOMIDE, GENOMIC ANALYSIS, GRADE, GLIOBLASTOMA, IDH, TUMORS, CLASSIFICATION, RADIOTHERAPY
Downloads
-
(...).pdf
- full text (Published version)
- |
- UGent only
- |
- |
- 299.75 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-01HKWV4CFWT0SARGD2Q4RRTEMX
- MLA
- Pinson, Harry, et al. “Epidemiology and Survival of Adult-Type Diffuse Glioma in Belgium during the Molecular Era.” NEURO-ONCOLOGY, vol. 26, no. 1, Oxford Univ Press Inc, 2024, pp. 191–202, doi:10.1093/neuonc/noad158.
- APA
- Pinson, H., Silversmit, G., Vanhauwaert, D., Vanschoenbeek, K., Kalala Okito, J.-P., De Vleeschouwer, S., … De Gendt, C. (2024). Epidemiology and survival of adult-type diffuse glioma in Belgium during the molecular era. NEURO-ONCOLOGY, 26(1), 191–202. https://doi.org/10.1093/neuonc/noad158
- Chicago author-date
- Pinson, Harry, Geert Silversmit, Dimitri Vanhauwaert, Katrijn Vanschoenbeek, Jean-Pierre Kalala Okito, Steven De Vleeschouwer, Tom Boterberg, and Cindy De Gendt. 2024. “Epidemiology and Survival of Adult-Type Diffuse Glioma in Belgium during the Molecular Era.” NEURO-ONCOLOGY 26 (1): 191–202. https://doi.org/10.1093/neuonc/noad158.
- Chicago author-date (all authors)
- Pinson, Harry, Geert Silversmit, Dimitri Vanhauwaert, Katrijn Vanschoenbeek, Jean-Pierre Kalala Okito, Steven De Vleeschouwer, Tom Boterberg, and Cindy De Gendt. 2024. “Epidemiology and Survival of Adult-Type Diffuse Glioma in Belgium during the Molecular Era.” NEURO-ONCOLOGY 26 (1): 191–202. doi:10.1093/neuonc/noad158.
- Vancouver
- 1.Pinson H, Silversmit G, Vanhauwaert D, Vanschoenbeek K, Kalala Okito J-P, De Vleeschouwer S, et al. Epidemiology and survival of adult-type diffuse glioma in Belgium during the molecular era. NEURO-ONCOLOGY. 2024;26(1):191–202.
- IEEE
- [1]H. Pinson et al., “Epidemiology and survival of adult-type diffuse glioma in Belgium during the molecular era,” NEURO-ONCOLOGY, vol. 26, no. 1, pp. 191–202, 2024.
@article{01HKWV4CFWT0SARGD2Q4RRTEMX, abstract = {{Background Survival data of diffuse adult-type glioma is mostly based on prospective clinical trials or small retrospective cohort studies. Real-world data with large patient cohorts is currently lacking.Methods Using the nationwide, population-based Belgian Cancer Registry, all known histological reports of patients diagnosed with an adult-type diffuse glioma in Belgium between 2017 and 2019 were reviewed. The ICD-O-3 morphology codes were matched with the histological diagnosis. The gathered data were transformed into the 2021 World Health Organization classification of CNS tumors using the IDH- and 1p/19q-mutation status.Results Between 2017 and 2019, 2233 diffuse adult-type gliomas were diagnosed in Belgium. Full molecular status was available in 67.1% of identified cases. The age-standardized incidence rate of diffuse adult-type glioma in Belgium was estimated at 8.55 per 100 000 person-years and 6.72 per 100 000 person-years for grade 4 lesions. Median overall survival time in IDH-wild-type glioblastoma was 9.3 months, significantly shorter compared to grade 4 IDH-mutant astrocytoma (median survival time: 25.9 months). The 3-year survival probability was 86.0% and 75.7% for grades 2 and 3 IDH-mutated astrocytoma. IDH-wild-type astrocytoma has a worse prognosis with a 3-year survival probability of 31.6% for grade 2 and 5.7% for grade 3 lesions.Conclusions This registry-based study presents a large cohort of adult-type diffuse glioma with known molecular status and uses real-world survival data. It adds to the current literature which is mainly based on historical landmark trials and smaller retrospective cohort studies.}}, author = {{Pinson, Harry and Silversmit, Geert and Vanhauwaert, Dimitri and Vanschoenbeek, Katrijn and Kalala Okito, Jean-Pierre and De Vleeschouwer, Steven and Boterberg, Tom and De Gendt, Cindy}}, issn = {{1522-8517}}, journal = {{NEURO-ONCOLOGY}}, keywords = {{diffuse adult-type glioma,epidemiology,survival,RANDOMIZED PHASE-III,CENTRAL-NERVOUS-SYSTEM,ADJUVANT TEMOZOLOMIDE,GENOMIC ANALYSIS,GRADE,GLIOBLASTOMA,IDH,TUMORS,CLASSIFICATION,RADIOTHERAPY}}, language = {{eng}}, number = {{1}}, pages = {{191--202}}, publisher = {{Oxford Univ Press Inc}}, title = {{Epidemiology and survival of adult-type diffuse glioma in Belgium during the molecular era}}, url = {{http://doi.org/10.1093/neuonc/noad158}}, volume = {{26}}, year = {{2024}}, }
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: